[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549400":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":34,"responsibleParty":50,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Centrum Clinic IVF Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Women defined as poor responders according to POSEIDON criteria group 4 undergoing IVF",null,"This group of women, who have low serum AMH levels and low antral follicle count obviusly reveal unfavorable ovarian stimulation and reproductive outcomes in daily practice. Since the most important outcome measure is the live birth rate in assisted reproduction, rates have been reportedly very low for this cohort. Depending from the reports, live birth rates particularly cumulative rates directly correlated with collected numbers of oocytes. Therefore, studies should focus on this entity.",[13],"Other: Ovulation Trigger Timing Based on Leading Follicle Size in POSEIDON Group 4 IVF Patients",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Ovulation Trigger Timing Based on Leading Follicle Size in POSEIDON Group 4 IVF Patients","In this study, ovulation trigger timing is determined according to the diameter of the leading follicle measured by transvaginal ultrasound during ovarian stimulation in women classified as POSEIDON group 4. Patients undergoing controlled ovarian stimulation are monitored with serial ultrasound examinations and serum hormone measurements. Ovulation triggering is performed when the leading follicle reaches predefined size categories. The study evaluates the association between the diameter of the leading follicle at the time of trigger and reproductive outcomes. The primary outcome measure is the number of metaphase II (MII) oocytes retrieved, while secondary outcomes include blastocyst formation and pregnancy outcomes.",[9],[20],{"name":21,"affiliation":22,"role":23},"Emre Pabuccu, Prof.","Ufuk University","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Emre G Pabuccu, Professor","CONTACT","+90 532 4147844","emregpabuccu@gmail.com",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Recai Pabuccu, Professor","+90 532 6160086","pabuccu@hotmail.com",[35],{"facility":5,"status":36,"city":37,"state":37,"zip":38,"country":39,"countryCode":10,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Ankara","06800","Turkey (Türkiye)",{"type":41,"coordinates":42},"Point",[43,44],32.85427,39.91987,{"lat":44,"lon":43},[47],{"name":48,"role":27,"phone":49,"phoneExt":10,"email":10},"Emre Pabuccu","05324147844",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Emre Göksan Pabuçcu","Professor","100549400","best-size-for-ovulation-triggering-in-poseidon-4-patients-best-4-study-100549400",false,"NCT06433518","BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study)","What Should Be The Optimal Ovulation Triggering Size in Poseidon Group 4 Patients Undergoing Ovarian Stimulation?","BEST","Inclusion Criteria:\n\n* Women age equal to or greater than 35 years\n* Women with low serum AMH (\\\u003C1,2 ng\u002Fml),\n* women with low AFC (\\\u003C5)\n* women Undergoing assisted reproduction with Short antagonist protocol or long -agonist protocol\n* women who used Max daily gonadotropin dose of 300 IU\n\nExclusion Criteria:\n\n* Age \\\u003C35 years.\n* Ovarian reserve parameters not meeting the POSEIDON group 4 definition.\n* Natural or modified natural cycles without controlled ovarian stimulation.\n* In vitro maturation (IVM) cycles.\n* Luteal-phase stimulation or DuoStim protocols.\n* Preimplantation genetic testing (PGT-A, PGT-M, or PGT-SR) cycles, unless prespecified for stratified analyses.\n* Major untreated uterine cavity pathology (e.g., submucosal fibroids, significant intrauterine adhesions, congenital uterine anomalies) or untreated hydrosalpinx.\n* Cycles with missing or incomplete follicular measurement data on the trigger day.\n* Cycles with non-standardized or undocumented trigger-to-oocyte retrieval intervals.","FEMALE","35 Years","44 Years",{"count":66,"type":67},200,"ESTIMATED","9 Months","OBSERVATIONAL","This observational clinical study aims to determine the optimal timing of ovulation triggering in women aged 35 and above with poor ovarian reserve.\n\nFor this purpose, cases undergoing ovarian stimulation for assisted reproductive treatment and planned final oocyte triggering will be evaluated in two separate groups:\n\n1. \\*\\*Experimental Group\\*\\*: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.\n2. \\*\\*Control Group\\*\\*: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.\n\nAll triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.\n\nThe primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.\n\nPrimary and secondary outcomes will be compared between the two groups.",[72,73],"Fertilization","Fertilization in Vitro",[75,76,77,78],"oocyte","IVF","poor responder","ovarian stimulation","2026-03-17",{"date":81,"type":82},"2026-03-19","ACTUAL",{"date":84,"type":82},"2026-03-15",{"date":86,"type":67},"2026-12-30",{"name":5,"class":6},1]